Olmesartan Medoxomil
FDA-approved product (tablet, oral), marketed as Benicar, Olmesartan Medoxomil.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Cardiovascular disease
- Diabetes mellitus
- Heart failure
- Hypertension
- Myocardial infarction
- Stroke
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Angiotensin ii receptor blockers (arbs), plain
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA49.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli42.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae26.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis55.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Olmesartan Medoxomil with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Trimetrexate GlucuronateExisting use: Other agents against amoebiasis and other protozoal diseases88.6% AI-predicted activityagainst E. coliLab records exist17 registered studies
- Folic AcidExisting use: Acne, Anemia, Anemia (phenotype) and 8 more87.0% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- MethotrexateExisting use: Acute lymphoblastic leukemia, Adenoma, Arthritis and 21 more86.8% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- PralatrexateExisting use: Cancer, Mature T-cell and NK-cell non-Hodgkin lymphoma, Neoplasm and 2 more82.2% AI-predicted activityagainst E. coli44 registered studies
- TriclosanExisting use: Phenol and derivatives, Medicated dressings with antiinfectives81.0% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- Leucovorin CalciumExisting use: Osteosarcoma67.6% AI-predicted activityagainst E. coli50+ registered studies
- LevoleucovorinExisting use: Anemia, Colorectal adenocarcinoma, Colorectal cancer and 3 more67.6% AI-predicted activityagainst E. coli50+ registered studies
- PyrimethamineExisting use: Malaria, Toxoplasmosis64.6% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- Copanlisib DihydrochlorideExisting use: Follicular lymphoma, Neoplasm, Neoplasm of mature B-cells63.5% AI-predicted activityagainst E. coli10 registered studies
- AfamelanotideExisting use: Erythropoietic protoporphyria62.6% AI-predicted activityagainst E. coli23 registered studies
- Rimegepant SulfateExisting use: Migraine disorder61.6% AI-predicted activityagainst E. coli50+ registered studies
- Histrelin AcetateExisting use: Neoplasm, Prostate adenocarcinoma, Prostate cancer61.6% AI-predicted activityagainst E. coli13 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Olmesartan on Ambulatory Blood Pressure Change
NCT00854763 · start 2009-04
Registered record
- Registry ID
- NCT00854763
- Conditions
- Hypertension
- Interventions
- olmesartan
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Unknown
- Start
- 2009-04
- Completion
- Not recorded
- Enrolment
- 100
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypertensionInterventionolmesartanPhaseNot recordedRegistry statusUnknownEffect of Two Doses of Olmesartan Medoxomil and Amlodipine on Vascular Markers in Hypertensive Patients With Metabolic Syndrome
NCT00891267 · start 2008-10
Registered record
- Registry ID
- NCT00891267
- Conditions
- Metabolic Syndrome; Hypertension
- Interventions
- Olmesartan medoxomil tablets low dose; Olmesartan medoxomil tablets high dose; Amlodipine
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2008-10
- Completion
- 2011-05
- Enrolment
- 60
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMetabolic Syndrome; HypertensionInterventionOlmesartan medoxomil tablets low dose; Olmesartan medoxomil tablets high dose; AmlodipinePhasePhase 3Registry statusCompletedPrognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment
NCT00741585 · start 2008-09-01
Registered record
- Registry ID
- NCT00741585
- Conditions
- Essential Hypertension; Cardiovascular Disease; Stroke; Chronic Kidney Disease
- Interventions
- Any antihypertensive medication alone or in combination; Any antihypertensive medication alone or in combination; Ambulatory blood pressure monitoring
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2008-09-01
- Completion
- 2018-06-30
- Enrolment
- 21,983
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionEssential Hypertension; Cardiovascular Disease; Stroke; Chronic Kidney DiseaseInterventionAny antihypertensive medication alone or in combination; Any antihypertensive medication alone or in combination; Ambulatory blood pressure monitoringPhasePhase 4Registry statusCompletedOlmesartan/HCTZ 40/12.5 mg Combination Therapy Versus Olmesartan Medoxomil 40 mg Monotherapy in Essential Hypertension
NCT00441350 · start 2007-07
Registered record
- Registry ID
- NCT00441350
- Conditions
- Hypertension
- Interventions
- OM 40; OM/HCTZ 40/12.5
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2007-07
- Completion
- 2008-05
- Enrolment
- 1,004
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypertensionInterventionOM 40; OM/HCTZ 40/12.5PhasePhase 3Registry statusCompletedPost-Marketing Surveillance Of Olmesartan Medoxomil In Combination With Hydrochlorothiazide
NCT00796159 · start 2007-07
Registered record
- Registry ID
- NCT00796159
- Conditions
- Hypertension
- Interventions
- Olmesartan medoxomil
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2007-07
- Completion
- 2008-12
- Enrolment
- 1,723
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypertensionInterventionOlmesartan medoxomilPhaseNot recordedRegistry statusCompletedAssessment of the Effectiveness of OLMETEC® and OLMETEC PLUS® for Treatment of Hypertension in Stage I and II Patients (Study P05254)(COMPLETED)
NCT00811226 · start 2007-04
Registered record
- Registry ID
- NCT00811226
- Conditions
- Hypertension
- Interventions
- olmesartan medoxomile alone or combined with hydrochlorothiazide,
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2007-04
- Completion
- 2008-01
- Enrolment
- 450
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypertensionInterventionolmesartan medoxomile alone or combined with hydrochlorothiazide,PhaseNot recordedRegistry statusCompletedA Study of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Stage I and Stage II Hypertension
NCT00430638 · start 2006-12
Registered record
- Registry ID
- NCT00430638
- Conditions
- Hypertension
- Interventions
- olmesartan medoxomil + hydrochlorothiazide, if necessary; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2006-12
- Completion
- 2007-10
- Enrolment
- 278
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypertensionInterventionolmesartan medoxomil + hydrochlorothiazide, if necessary; PlaceboPhasePhase 4Registry statusCompletedFasting Study of Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg and Benicar HCT® Tablets 40 mg/25 mg
NCT01020214 · start 2006-11
Registered record
- Registry ID
- NCT01020214
- Conditions
- Healthy
- Interventions
- Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg; Benicar HCT® Tablets 40 mg/25 mg
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2006-11
- Completion
- 2006-11
- Enrolment
- 36
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventionOlmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg; Benicar HCT® Tablets 40 mg/25 mgPhasePhase 1Registry statusCompletedEfficacy and Safety of Olmesartan Medoxomil in Stage 1 and 2 Essential Hypertension
NCT00890591 · start 2006-08
Registered record
- Registry ID
- NCT00890591
- Conditions
- Essential Hypertension
- Interventions
- olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2006-08
- Completion
- 2007-08
- Enrolment
- 144
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionEssential HypertensionInterventionolmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessaryPhasePhase 4Registry statusCompletedThe Japan-Combined Treatment With Olmesartan and a Calcium Channel Blocker Versus Olmesartan and Diuretics Randomized Efficacy Study (J-CORE)
NCT00607035 · start 2006-05
Registered record
- Registry ID
- NCT00607035
- Conditions
- Hypertension
- Interventions
- Olmesartan medoxomil ＋Azelnidipine; Olmesartan medoxomil + Hydrochlorothiazide
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2006-05
- Completion
- 2008-05
- Enrolment
- 220
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypertensionInterventionOlmesartan medoxomil ＋Azelnidipine; Olmesartan medoxomil + HydrochlorothiazidePhasePhase 4Registry statusCompletedOlmesartan and an add-on Treatment in Patients With Mild to Moderate Hypertension
NCT00311155 · start 2006-03
Registered record
- Registry ID
- NCT00311155
- Conditions
- Essential Hypertension
- Interventions
- olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2006-03
- Completion
- 2008-04
- Enrolment
- 694
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionEssential HypertensionInterventionolmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessaryPhasePhase 4Registry statusCompletedFed Study of Olmesartan Medoxomil Tablets 40 mg and Benicar® Tablets 40 mg
NCT00648219 · start 2005-12
Registered record
- Registry ID
- NCT00648219
- Conditions
- Healthy
- Interventions
- Olmesartan Medoxomil Tablets 40 mg; Benicar® Tablets 40 mg
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2005-12
- Completion
- 2006-01
- Enrolment
- 36
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventionOlmesartan Medoxomil Tablets 40 mg; Benicar® Tablets 40 mgPhasePhase 1Registry statusCompletedFasting Study of Olmesartan Medoxomil Tablets 40 mg and Benicar® Tablets 40 mg
NCT00649623 · start 2005-12
Registered record
- Registry ID
- NCT00649623
- Conditions
- Healthy
- Interventions
- Olmesartan Medoxomil Tablets 40 mg; Benicar® Tablets 40 mg
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2005-12
- Completion
- 2005-12
- Enrolment
- 36
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventionOlmesartan Medoxomil Tablets 40 mg; Benicar® Tablets 40 mgPhasePhase 1Registry statusCompletedRenin Profiling in Selection of Initial Antihypertensive Drug
NCT00834600 · start 2005-12
Registered record
- Registry ID
- NCT00834600
- Conditions
- Hypertension
- Interventions
- olmesartan, hydrochlorothiazide, amlodipine; hydrochlorothiazide (HCTZ) or olmesartan
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2005-12
- Completion
- 2011-10
- Enrolment
- 185
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypertensionInterventionolmesartan, hydrochlorothiazide, amlodipine; hydrochlorothiazide (HCTZ) or olmesartanPhaseNot applicableRegistry statusCompletedTrial to Investigate the Efficacy of Olmesartan in Paroxysmal Atrial Fibrillation
NCT00098137 · start 2005-01
Registered record
- Registry ID
- NCT00098137
- Conditions
- Heart Disease; Arrhythmia; Atrial Fibrillation
- Interventions
- Olmesartan
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2005-01
- Completion
- 2009-05
- Enrolment
- 422
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHeart Disease; Arrhythmia; Atrial FibrillationInterventionOlmesartanPhasePhase 3Registry statusCompleted